Whitehawk Therapeutics opened lower at $3.21, compared with its previous close of $3.24. In the last trading session, the stock traded between $3.00 and $3.21. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 2 years ago in Whitehawk Therapeutics is now worth
$ 152.33
Giving a profit of
$ 52.33 (52.33%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 2 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.16 (-5.03%)
Day High
$3.21
Day Low
$3.00
Day Open
$3.21
Prev Close
$3.24
Volume
2,83,061
1W Return
-2.60%
1M Return
-8.59%
3M Return
-34.11%
6M Return
-19.03%
1Y Return
37.98%
Fundamentals
Market Cap ($ Mn)
182
PE Ratio
-
PB Ratio
1.44
PEG Ratio
-
ROE
-13.92%
ROCE
-18.11%
EPS (TTM)
$-0.36
Investment Returns
1 Week
-2.60%
1 Month
-8.59%
3 Months
-34.11%
6 Months
-19.03%
9 Months
8.73%
Financials
Quarterly
All values in $ Mn
7.1
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Jun 26
0.0
Sep 26
Updates
9Nov
Whitehawk Therapeutics Q3 Results: Loss narrows 12% YoY to $(0.23)
Whitehawk Therapeutics reported a Q3 loss of $(0.23) per share. The result missed the analyst consensus estimate of $(0.21) by 9.52%. Per-share loss narrowed 11.54% YoY from $(0.26) in the prior year.
3 days ago
1Oct
Whitehawk presents real-world data supporting MUC16 target in ovarian cancer
Whitehawk presented two real-world analyses on MUC16 expression. High MUC16 levels associated with poor overall survival in ovarian cancer. Expression remained stable after standard-of-care therapies. Findings support development of ADC candidate HWK-016.
1mo ago
14Sep
Whitehawk Therapeutics presents PTK7 stability data for NSCLC at WCLC 2026
Whitehawk Therapeutics presented data at WCLC 2026 supporting PTK7 as a durable ADC target in EGFR wild-type NSCLC. PTK7 expression remained stable after standard-of-care therapies, showing less variation than MET, PD-L1, and ITGB6. Real-world survival was not impacted by PTK7 levels, confirming its role as a target-engagement biomarker rather than prognostic marker. Findings support the development of HWK-007, currently in Phase 1 trials for NSCLC, ovarian, and endometrial cancers.
2mo ago
14Jul
Leerink initiates coverage on Whitehawk Therapeutics with Outperform rating
Leerink Partners analyst Jonathan Chang initiates coverage on Whitehawk Therapeutics with an Outperform rating and a price target of $9. The stock is listed on NASDAQ under the ticker WHWK.
